These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 35358643)
1. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. Seow HC; Liao Q; Lau ATY; Leung SWS; Yuan S; Lam JKW Int J Pharm; 2022 May; 619():121704. PubMed ID: 35358643 [TBL] [Abstract][Full Text] [Related]
2. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation. Seow HC; Cai JP; Pan HW; Luo C; Wen K; Situ J; Wang K; Cao H; Leung SWS; Yuan S; Lam JKW J Control Release; 2023 Jun; 358():128-141. PubMed ID: 37084889 [TBL] [Abstract][Full Text] [Related]
3. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition. Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259 [TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of thin-film freeze-dried monoclonal antibodies using a powder nasal spray system. Yu YS; Xu H; AboulFotouh K; Williams G; Suman J; Sahakijpijarn S; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z Int J Pharm; 2024 Mar; 653():123892. PubMed ID: 38350499 [TBL] [Abstract][Full Text] [Related]
5. Development of favipiravir dry powders for intranasal delivery: An integrated cocrystal and particle engineering approach via spray freeze drying. Wong SN; Li S; Low KH; Chan HW; Zhang X; Chow S; Hui B; Chow PCY; Chow SF Int J Pharm; 2024 Mar; 653():123896. PubMed ID: 38346602 [TBL] [Abstract][Full Text] [Related]
6. Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler. Longest PW; Golshahi L; Behara SR; Tian G; Farkas DR; Hindle M J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):189-201. PubMed ID: 25192072 [TBL] [Abstract][Full Text] [Related]
7. Effect of formulation and inhaler parameters on the dispersion of spray freeze dried voriconazole particles. Liao Q; Lam ICH; Lin HHS; Wan LTL; Lo JCK; Tai W; Kwok PCL; Lam JKW Int J Pharm; 2020 Jun; 584():119444. PubMed ID: 32445908 [TBL] [Abstract][Full Text] [Related]
8. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations. Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460 [TBL] [Abstract][Full Text] [Related]
9. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. Saha T; Lyons N; Yue Yung DB; Quiñones-Mateu ME; Pletzer D; Das SC Eur J Pharm Biopharm; 2024 Feb; 195():114170. PubMed ID: 38128743 [TBL] [Abstract][Full Text] [Related]
10. Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy. Albariqi AH; Ke WR; Khanal D; Kalfas S; Tang P; Britton WJ; Drago J; Chan HK J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):239-251. PubMed ID: 35275749 [No Abstract] [Full Text] [Related]
11. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466 [TBL] [Abstract][Full Text] [Related]
12. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers. Li X; Vogt FG; Hayes D; Mansour HM J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451 [TBL] [Abstract][Full Text] [Related]
13. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Son YJ; Worth Longest P; Hindle M Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343 [TBL] [Abstract][Full Text] [Related]
14. Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children. Farkas D; Hindle M; Bonasera S; Bass K; Longest W J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):83-98. PubMed ID: 31464559 [No Abstract] [Full Text] [Related]
15. Powder aerosol delivery through nasal high-flow system: In vitro feasibility and influence of process conditions. Okuda T; Tang P; Yu J; Finlay WH; Chan HK Int J Pharm; 2017 Nov; 533(1):187-197. PubMed ID: 28830783 [TBL] [Abstract][Full Text] [Related]
17. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying. Saboti D; Maver U; Chan HK; Planinšek O J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981 [TBL] [Abstract][Full Text] [Related]
18. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria. Wang J; Kutter JP; Mu H; Moodley A; Yang M Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003 [TBL] [Abstract][Full Text] [Related]
19. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations. Hassan A; Farkas D; Longest W; Hindle M Int J Pharm; 2020 Dec; 591():120027. PubMed ID: 33130220 [TBL] [Abstract][Full Text] [Related]
20. Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. Pozzoli M; Rogueda P; Zhu B; Smith T; Young PM; Traini D; Sonvico F Drug Dev Ind Pharm; 2016 Oct; 42(10):1660-8. PubMed ID: 26953090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]